drugset / Trial / NCT01831089

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

NCT01831089

Phase 1 Completed 69 enrolled PharmaMar
NaSingle-groupOpen-labelTreatment

Summary

Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors

Timeline

Start
2013-09
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody
Subject Lurbinectedin Other / unclassified
Background Paclitaxel Small molecule